Detalhe da pesquisa
1.
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).
Blood
; 123(22): 3398-405, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615778
2.
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Blood
; 123(22): 3406-13, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615776
3.
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Blood
; 123(22): 3390-7, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24615777